Efficacy of Clonidine and Propranolol in Dentistry (AAA)
Information source: CES University
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Anxiety
Intervention: Clonidine (Drug); Propranolol (Drug); Placebo (Drug)
Phase: Phase 2
Sponsored by: CES University
Official(s) and/or principal investigator(s):
Patricia Bermudez, Dentistry, Principal Investigator, Affiliation: CES University
Libia M Rodriguez, Magister, Study Director, Affiliation: CES University
Ana K Tamara, Physician, Principal Investigator, Affiliation: CES University
The aim of the study is to determine the efficacy of clonidine and propranolol for transient
anxiety management and intra and postoperative pain in patients undergoing ambulatory
surgery of third molar.
Official title: Efficacy of Clonidine and Propranolol Versus Placebo for the Control of Anxiety During Surgical Procedures in Dentistry
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Change from baseline in modified dental anxiety scale(MDAS)and vital signs (blood pressure, heart rate, respiratory rate, oxygen saturation) until four hours post treatment
Secondary outcome: Changes in Verbal Numerical Rating Scale (VNRS) at three, six, and twenty-four hours post treatment
There will be a randomized, triple-blind, placebo-controlled clinical trial with parallel
group design to determine the efficacy of the pre medication propranolol and clonidine
versus placebo for reducing anxiety during third molar removal surgery. Patients will be
assigned to 3 groups of 20 patients each. One group will receive 150 mcg of clonidine, the
second group will receive propranolol 40mg, and the control group will receive placebo. The
modified dental anxiety scale will be applied before and after surgery in order to evaluate
the change in anxiety level, which will be assessed as the primary outcome. The secondary
outcomes include the measurement of changes in blood pressure, heart rate and respiratory
rate evaluated before, during and after surgery. Additionally, pain will be assessed through
numerical pain scale at 3, 6 and 24 hours after surgery. Also, possible side effects will be
identified (vomiting, nausea, dry mouth, dizziness and drowsiness). Statistical analysis:
qualitative variables will be described by absolute and relative frequencies, and
quantitative variables will be described by the mean along with standard deviation or the
median with interquartile range depending on the distribution of the data. One-way ANOVA or
Kruskal Wallis will be used (depending on the fulfillment of assumptions) in order to
compare the quantitative variables amongst the groups. The chi squared test will be used to
compare the qualitative variables. The confidence intervals will be estimated at 95% for all
effect magnitude measurements calculated.
Minimum age: 14 Years.
Maximum age: 40 Years.
- Normotensive patients and pre-hypertension who are undergoing elective surgery for
removal of third molars.
- Age range 14 to 40 years
- Patients with dental anxiety above 13 points on the scale (MDAS).
- People who voluntarily agree to participate in the study and sign the informed
- Patients receiving any medication for any chronic pathology.
- Patients of African American race, being more likely to have abnormal blood pressure.
- Patients with a history of cardiovascular disease.
- Patients with chronic systemic disease such as diabetes, hyper or hypothyroidism,
Addison's syndrome, renal failure, hypertension or liver disease.
- Pregnant or breastfeeding.
- Patients diagnosed with anxiety disorder or depressive disorder
Locations and Contacts
Cooperative University, Envigado, Antioquia, Colombia; Recruiting
Patricia Bermudez, Dentistry, Email: firstname.lastname@example.org
Ana K Tamara, Physician, Email: email@example.com
Ng SK, Leung WK. A community study on the relationship of dental anxiety with oral health status and oral health-related quality of life. Community Dent Oral Epidemiol. 2008 Aug;36(4):347-56.
Kvale G, Berggren U, Milgrom P. Dental fear in adults: a meta-analysis of behavioral interventions. Community Dent Oral Epidemiol. 2004 Aug;32(4):250-64.
Lago-Méndez L, Diniz-Freitas M, Senra-Rivera C, Seoane-Pesqueira G, Gándara-Rey JM, García-García A. Postoperative recovery after removal of a lower third molar: role of trait and dental anxiety. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Dec;108(6):855-60. doi: 10.1016/j.tripleo.2009.07.021.
Humphris GM, Dyer TA, Robinson PG. The modified dental anxiety scale: UK general public population norms in 2008 with further psychometrics and effects of age. BMC Oral Health. 2009 Aug 26;9:20. doi: 10.1186/1472-6831-9-20.
Hall DL, Tatakis DN, Walters JD, Rezvan E. Oral clonidine pre-treatment and diazepam/meperidine sedation. J Dent Res. 2006 Sep;85(9):854-8.
Liu HH, Milgrom P, Fiset L. Effect of a beta-adrenergic blocking agent on dental anxiety. J Dent Res. 1991 Sep;70(9):1306-8.
Herr KA, Spratt K, Mobily PR, Richardson G. Pain intensity assessment in older adults: use of experimental pain to compare psychometric properties and usability of selected pain scales with younger adults. Clin J Pain. 2004 Jul-Aug;20(4):207-19.
Starting date: August 2012
Last updated: February 2, 2013